Etentamig vs Teclistamab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA x CD3 · full Multiple Myeloma pipeline
Etentamig
Developed by AbbVie
NCT06158841 · Phase 3 · active, not recruiting
This was a randomized, open-label Phase 3 trial with 421 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-03. An open-label trial is never graded strong; with a sponsor-reported result, the grade is moderate.
Next expected readout: February 2027 · NCT06223516 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) (Up to Approximately 5 Years); Objective Response Rate (ORR) (Up to Approximately 5 Years): Dual primary endpoints met: objective response rate and progression-free survival vs standard available therapies (PFS HR 0.40, P<0.0001) (AbbVie, 2026-09-03). (met)
Result source: NCT06158841
Teclistamab
Marketed by Johnson & Johnson
NCT05083169 · Phase 3 · active, not recruiting
MajesTEC-3 was a randomized, open-label Phase 3 comparing teclistamab plus daratumumab with daratumumab-based standard regimens (DPd or DVd) in relapsed multiple myeloma. Its primary endpoint, progression-free survival, is a clinical outcome and was met. An open-label trial is never graded strong under the rubric.
Next expected readout: November 2026 · NCT06505369 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) (Up to 5 years): Primary endpoint, progression-free survival: teclistamab plus daratumumab was statistically significant and superior to DPd/DVd (J&J, 2025-10-16). (met)
Result source: NCT05083169
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Etentamig | Teclistamab |
|---|---|---|
| PFS, median | —Trial running · NCT07095452 | —Trial running · NCT07887984 |
| OS, median | —Trial running · NCT07095452 | —Trial running · NCT07887984 |
| ORR | —Trial running · NCT07095452 | —Trial running · NCT07887984 |
| VGPR or better | —Trial running · NCT07095452 | —Trial running · NCT07887984 |
| MRD negativity | —Trial running · NCT07095452 | —Trial running · NCT07887984 |
PFS, median
- Etentamig
- —Trial running · NCT07095452
- Teclistamab
- —Trial running · NCT07887984
OS, median
- Etentamig
- —Trial running · NCT07095452
- Teclistamab
- —Trial running · NCT07887984
ORR
- Etentamig
- —Trial running · NCT07095452
- Teclistamab
- —Trial running · NCT07887984
VGPR or better
- Etentamig
- —Trial running · NCT07095452
- Teclistamab
- —Trial running · NCT07887984
MRD negativity
- Etentamig
- —Trial running · NCT07095452
- Teclistamab
- —Trial running · NCT07887984
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Etentamig's landscape · Teclistamab's landscape